SCHEMBL5545697

SCHEMBL5545697

C[C@H](O)CNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(CC(N)=O)c1=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
CNR2 P34972 7/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 1/20 0.36
TLR2 O60603 2/20 0.36
ACSS2 Q9NR19 3/20 0.35
CNR1 P21554 1/20 0.34
LMNA P02545 2/20 0.34
TSHR P16473 2/20 0.34
HTT P42858 2/20 0.34
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HIF1A Q16665 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541165 0.90 L3MBTL1 (0.52) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL16991731 0.90 L3MBTL1 (0.41) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL5540909 0.90 L3MBTL1 (0.41) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL5540595 0.89 L3MBTL1 (0.41) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL5538628 0.88 L3MBTL1 (0.41) L3MBTL1CNR2MEN1KMT2AHSD17B10
SCHEMBL5541038 0.88 GRIN2B (0.40) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL5545538 0.87 L3MBTL1 (0.41) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL5545774 0.87 CNR2 (0.42) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL5538489 0.87 POLB (0.45) L3MBTL1CNR2MEN1KMT2AALDH1A1
SCHEMBL5545917 0.87 POLB (0.45) L3MBTL1CNR2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 L3MBTL1 1411/4885CNR2 3954/4885MEN1 4802/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 L3MBTL1 1408/4885CNR2 4810/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.